MedTrace Logo

Study to Evaluate Efficacy, Safety, Tolerability and Pharmacokinetics of AZD1386 in Patients With Peripheral Neuropathic Pain

NCT00976534 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2009-12-23

No results posted yet for this study

Summary

The primary aim of this study is to investigate if AZD1386 is efficacious as an analgesic in patients with peripheral neuropathic pain. This will be done by comparing the effect of AZD1386 to placebo ("inactive substance") on pain.

Conditions

  • Pain
  • Neuropathic Pain

Interventions

DRUG

AZD1386

90 mg, capsules, oral, during 3 weeks

DRUG

Placebo

capsules, oral, during 3 weeks

Sponsors & Collaborators

Principal Investigators

  • Richard L Leff, md · AstraZeneca R&D Wilmington, USA

  • Rolf Karlsten, MD · AstraZeneca R&D Södertälje, Sweden

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Completion
2010-02-28

Countries

  • Canada
  • Denmark
  • France
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00976534 on ClinicalTrials.gov